Inflammatory brain disorders encompass a broad spectrum of conditions characterized by inflammation within the brain tissue. This umbrella term includes ailments such as encephalitis, meningitis, and autoimmune disorders affecting the central nervous system (CNS). Encephalitis, for instance, involves inflammation of the brain parenchyma, often instigated by viral infections like the herpes simplex virus or autoimmune reactions where the body's immune system erroneously targets its own brain tissue. Meningitis, on the other hand, refers to inflammation of the protective membranes enveloping the brain and spinal cord, typically triggered by bacterial or viral infections. Autoimmune inflammatory disorders of the CNS, such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), result from the immune system mistakenly attacking the myelin sheath, disrupting nerve signals and leading to various neurological symptoms like cognitive impairment, motor dysfunction, and sensory disturbances. Diagnosis of these disorders typically involves a thorough neurological examination, imaging studies such as MRI scans, and analysis of cerebrospinal fluid obtained via lumbar puncture. Treatment approaches vary depending on the underlying cause and may include antiviral or antibiotic medications, immunosuppressive therapy, and supportive care to manage symptoms and prevent complications. Early detection and intervention are paramount in minimizing brain damage and improving outcomes for patients with inflammatory brain disorders.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States